Better Health for All

ICON plc's core business of outsourced drug development services inherently contributes to health benefits, with no evidence of harmful services. The company contributed to the development of 19 approved medicines.

ICON partnered with Martini Hospital to train staff in life-saving procedures, resulting in a certified training center for resuscitation. The company implemented the Modified Early Warning Score (MEWS) to proactively identify patient safety risks, noting that 80% of resuscitation cases had warning signs up to 24 hours beforehand. ICON focuses on expanding trial access and improving representation for all participants, trial investigators, and community and patient advocacy groups. The company emphasizes the ethical imperative of participant safety in early-phase clinical research.

Fair Money & Economic Opportunity

ICON plc is a global provider of outsourced drug development and commercialization services, not a financial institution.

The company's core business lies outside finance, and it does not offer lending, deposit, or other consumer financial services. Consequently, all KPIs related to financial products, pricing, fees, customer financial data, and lending practices are not applicable. While ICON created a scholarship program for underrepresented groups in STEM, this initiative does not fall under the definition of a 'loan/insurance book' for the inclusion_initiatives KPI.

Fair Pay & Worker Respect

For the 2023-24 period in the UK, women's median hourly pay was 28.4% lower than men's, meaning women earned 72p for every £1 earned by men.

Women's median bonus pay was 27.4% lower than men's. The company's overall employee satisfaction score is 65 out of 100, based on employee reviews. Voluntary employee turnover is reported to be between 50-60% annually, with many employees leaving within their first year.

Fair Trade & Ethical Sourcing

ICON requires all suppliers to certify compliance with its Global Supplier Code of Conduct or a materially equivalent internal code before doing business.

This code, effective October 2024 (version 6.0), applies globally to all ICON suppliers and incorporates the Pharmaceutical Supply Chain Initiative (PSCI) principles for responsible supply chain management. It outlines standards for ethics, compliance, labor, and human rights, and expects suppliers to ensure their own supply chains also comply with these principles.

Honest & Fair Business

ICON plc's Board of Directors has 8 members.

7 of whom are independent. This means 87.5% of the board members are independent.

Kind to Animals

ICON plc's Supplier Code of Conduct, effective October 2024, states that animal testing should be performed after considering replacement, reduction, or refinement of procedures to minimize distress, and alternatives should be used when scientifically valid and acceptable to regulators.

However, the company acquired Envigo, a provider of laboratory animal testing services, in January 2023, and its core business includes preclinical services involving animal testing. This indicates a public policy articulating reduction intent, but with inconsistent enforcement or a business model that heavily relies on animal testing.

No War, No Weapons

ICON plc is a global provider of outsourced drug development and commercialization services to pharmaceutical, biotechnology, and medical device companies, indicating a core business in civilian markets.

There is no evidence of the company's involvement in arms manufacturing, military contracts, or conflict facilitation. The company's Global Supplier Code of Conduct, updated October 2024, requires suppliers to comply with all applicable import and export controls, sanctions, and trade compliance laws, prohibiting involvement with entities from restricted countries/regions. Suppliers are also required to perform due diligence on critical raw materials to ensure products do not contain metals from Conflict Affected and High-Risk Areas (CAHRAs) that finance armed groups, and to comply with OECD Due Diligence Guidance and EU Conflict Minerals Regulation. ICON reserves the right to terminate contracts with non-compliant suppliers. The company is a signatory of the UN Global Compact.

Respect for Cultures & Communities

The provided articles consist entirely of 'page not found' errors or generic clinical trial registry information, none of which contain specific, concrete data points relevant to ICON plc's performance on 'Respect for Cultures & Communities'.

Therefore, no KPIs can be scored based on the evidence provided.

Safe & Smart Tech

ICON plc is certified to the EU-U.S. Data Privacy Framework (DPF), the UK Extension to the EU-U.S. DPF, and the Swiss-U.S. DPF.

The company explicitly states compliance with these frameworks, and mentions FDA and EU MDR regulations as relevant. There are no documented data breaches or incidents of unauthorized data use by ICON plc. However, the company has faced scrutiny for slow responses to cybersecurity vulnerabilities in medical devices, with examples of vulnerabilities and slow responses highlighted. The healthcare industry, in general, lags behind other sectors in medical device cybersecurity. ICON plc states it collects only relevant data and retains it only as needed, and individuals can opt out of disclosures and use for purposes different from original collection.